6DECEMBER - 2022TECH OUTLOOKEditorialStacey Smith Editor-in-Chiefeditor@pharmatechoutlook.comCOVID-19 prompted pharmaceutical companies and healthcare organizations to rethink how their businesses operate, including how technologies and digital solutions can improve the customer experience. Throughout the pandemic, pharma companies were thrown into the spotlight, playing a pivotal role in bringing lifesaving treatments to the masses at a breakneck pace. This gave rise to a demand for consultations from industry-specific experts offering professional advice, guidance, and actionable solutions to guide companies through the emerging production, testing, and regulatory compliance landscapes. Some of the facets consultation services boost for a pharma business includes drug development, regulatory affairs, scientific writing, economic affairs, quality assurance and compliance, real-world evidence (RWE), and pharmacovigilance (PV).Pharmaceutical companies are now increasingly required to demonstrate how a new drug improves patient outcomes, reduces the burden of the healthcare system as a whole, and worth its price. All these factors are boosting the demand for market access services including pharma strategy and consulting across the globe. As a key growth strategy, companies in the current healthcare market are focusing on expanding their portfolio with consulting services to leverage growth opportunities across the global market, which is driving private equities to make significant investments into the space.In this edition of Pharma Tech Outlook, we present to you some of the most promising pharma consulting service providers. The edition features thought leadership articles from Chris Braithwaite, SVP and global head of drug development technology at Novartis, Nick Thomson, senior director, chemical research and development at Pfizer Inc, and Kelly H. Zou, head of global medical analytics and real world evidence, Viatris. The edition also showcases innovative solutions from companies, including Hybrid Concepts International that supports the pharma sector in developing potential cures and The Medical Affairs Company (TMAC) that develops medical affairs solutions by adopting a boutique customer centric approach.Innovation and Expertise-Backed Consultation for Transformative Pharma ProjectsCopyright © 2022 ValleyMedia, Inc. All rights reserved. Reproduction in whole or part of any text, photography or illustrations without written permission from the publisher is prohibited. The publisher assumes no responsibility for unsolicited manuscripts, photographs or illustrations. Views and opinions expressed in this publication are not necessarily those of the magazine and accordingly, no liability is assumed by the publisher thereof.DECEMBER - 21 - 2022, Vol 08 - Issue 18 (ISSN 2644-2787) Published by ValleyMedia, Inc. To subscribe to Pharma Tech OutlookVisit www.pharmatechoutlook.com Disclaimer: *Some of the Insights are based on our interviews with CIOs and CXOsEditor-in-ChiefStacey SmithVisualizerRonald DonovanEditorial StaffAaron Pierce Ava GarciaJenna VegasCarolynn Walters Justin SmithPaul Barbersales@pharmatechoutlook.comeditor@pharmatechoutlook.commarketing@pharmatechoutlook.comEmail:Parley MeadowTECH OUTLOOKTECH OUTLOOK
< Page 5 | Page 7 >